No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
OGN240719P17500
- 0.05
- 0.000.00%
15min DelayTrading Jul 3 10:04 ET
0.00High0.00Low
0.00Open0.05Pre Close0 Volume546 Open Interest17.50Strike Price0.00Turnover44.94%IV12.62%PremiumJul 19, 2024Expiry Date0.00Intrinsic Value100Multiplier14DDays to Expiry0.05Extrinsic Value100Contract SizeAmericanOptions Type-0.0623Delta0.0686Gamma399.40Leverage Ratio-0.0072Theta-0.0005Rho-24.88Eff Leverage0.0049Vega
Intraday
- 5D
- Daily
News
Express News | NYSE Order Imbalance 104610.0 Shares on Buy Side
Express News | NYSE Order Imbalance 56041.0 Shares on Buy Side
Express News | NYSE Order Imbalance 107268.0 Shares on Buy Side
Express News | European Medicines Agency (EMA) Validates Henlius and Organon Filings for Prolia® and Xgeva® (Denosumab) Biosimilar Candidate Hlx14
Express News | NYSE Order Imbalance 91009.0 Shares on Sell Side
Organon & Co Spearheads Kahn Brothers' Strategic Portfolio Enhancements in Q1 2024
Comments
Organon's low P/E ratio is due to its predicted growth being less than the broader market. Shareholders accept this as they anticipate future earnings won't bring any pleasant surprises. The share price is unlikely to rise significantly soon under these conditions.
Organon & Co.'s (NYSE:OGN) Earnings Are Not Doing Enough For Some Investors 3
Analysts show increased negativity towards the business following recent results, reflected in a minor decrease in next year's EPS estimates. Despite predicted earnings decline, Organon's valuation is not expected to be significantly affected, but growth is anticipated to lag behind the industry.
1
1
Seeking Alpha analysts are growing more bullish on the Merck spinoff, despite Wall Street's neutral stance. Analysts Leo Nelissen and Gen Alpha highlight OGN's attractive yield as a reason for their Buy ratings.
1
Despite the company's payout ratio not posing an immediate concern, the significant decline in earnings per share raises concerns about Organon from a dividend perspective. Therefore, caution is advised for potential investors considering Organon for its upcoming dividend.
2
Read more